Progressing the knowledge associated with genetic functions as well as specific proteins known as transcription factors—able to promote or suppress specific genes throughout the life of cells and organisms—combined with a growing ability to turn on or off various gene expressions leads to the opportunity to create new medical therapies. That’s why funding this type of research powers this gene therapy-based future, from small studies to major programs—all this research can contribute to a greater body of cell therapy knowledge. Now thanks to a $300,000 grant from the National Science Foundation, an associate professor of biochemistry at Kennesaw State University can continue this important research. The monies will help Michael Van Dyke employ undergraduate researchers, expanding the body of knowledge and providing training for the next life science, gene-therapy-focused labor force.
Caltech trained Professor Van Dyke’s first study commenced thanks to an NSF grant back in 2017 but expired just at the end of June. Now the Georgia-based public research university professor can continue the investigation.
In this line of study, the Kennesaw University researcher ce...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).